Carrier, Lucie
Carrier, Lucie, 19..-...., biologiste
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Lucie Carrier médecin française
VIAF ID: 220171080 (Personal)
Permalink: http://viaf.org/viaf/220171080
Preferred Forms
-
100 1 _
‡a
Carrier, Lucie
-
100 1 _
‡a
Carrier, Lucie
-
100 1 _
‡a
Carrier, Lucie,
‡d
19..-....,
‡c
biologiste
-
100 0 _
‡a
Lucie Carrier
‡c
médecin française
4xx's: Alternate Name Forms (3)
5xx's: Related Names (1)
Works
| Title | Sources |
|---|---|
| Abnormal calcium release in skeletal muscle fibers of malignant hyperthermia susceptible pigs. |
|
| Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart |
|
| Anomalie de la libération de calcium dans les fibres musculaires squelettiques de porc atteints d'hyperthermie maligne |
|
| Anomalies génétiques de la cardiomyopathie hypertrophique familiale : de leur identification à l'analyse de leurs conséquences ex vivo et in vitro |
|
| Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice |
|
| Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms |
|
| Biologie et pathologie du coeur et des vaisseaux |
|
| Cardiomyopathy phenotypes in human-induced pluripotent stem cell-derived cardiomyocytes-a systematic review |
|
| Chronic activation of tubulin tyrosination improves heart function |
|
| Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice |
|
| Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function |
|
| Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy |
|
| Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice |
|
| The embryological basis of subclinical hypertrophic cardiomyopathy |
|
| Evaluation of the impact of microtubule modifications on cMyBP-C and hypertrophic cardiomyopathy |
|
| Exploration of altered molecular pathways involved in pathophysiology of LMNA-cardiomyopathy |
|
| From dilated cardiomyopathy characterization to therapeutic modulation of signaling pathways involved in the cardiac phenotype of genetic myopathies.. |
|
| The homozygous K280N troponin T mutation alters cross-bridge kinetics and energetics in human HCM |
|
| Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy |
|
| Identification de variants du gène FLNC dans les cardiomyopathies humaines et modélisations fonctionnelles chez la drosophile et dans des pseudo-tissus cardiaques |
|
| Impact of AT2 Receptor Deficiency on Postnatal Cardiovascular Development |
|
| Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice |
|
| Length and protein kinase A modulations of myocytes in cardiac myosin binding protein C-deficient mice |
|
| Localization of Islet-1-positive cells in the healthy and infarcted adult murine heart |
|
| Modeling of hypertrophic cardiomyopathy and assessment of gene therapy in human iPSC-derived cardiomyocytes |
|
| Modellierung der Hypertrophen Kardiomyopathie und Evaluierung von Gen-Therapien in humanen induziert pluripotenten Stammzell-Kardiomyozyten |
|
| Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice |
|
| MYBPC3 in hypertrophic cardiomyopathy: from mutation identification to RNA-based correction |
|
| Repair of Mybpc3 mRNA by 5'-trans-splicing in a Mouse Model of Hypertrophic Cardiomyopathy |
|
| Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice |
|
| Rôles et mécanismes d'action de la protéine Epac dans l'hypertrophie cardiaque |
|
| S100A4 as a target of the E3-Ligase Asb2β |
|
| Study of the functional consequences of BAG3 molecular variants associated with human dilated cardiomyopathy. |
|
| Targeted panel sequencing in pediatric primary cardiomyopathy supports a critical role of TNNI3 |
|
| Ubiquitin-proteasome system impairment caused by a missense cardiac myosin-binding protein C mutation and associated with cardiac dysfunction in hypertrophic cardiomyopathy |
|
| Unravelling the role of cardiac myosin-binding protein C (cMyBP-C) in the autophagy-lysosomal pathway |
|
